Evidence map›Paper›PMID 33210466›Full record

ArticleThoracic cancer2021

Is

Hang Li, Ting Ye, Nan Li, Guozhan Xia, Bin Li, Yang Zhang, Hong Hu, Yihua Sun, Yawei Zhang, Jiaqing Xiang and 9 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03689439 (Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer?), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03689439 completednot on this map

Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer?

TypeobservationalSponsorFudan UniversityRan2018 to 2022Enrolled1,000ConditionsBone MetastasesArmsbone scintigraphy
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Thoracic cancer · 2022
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Hang LiDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Ting YeDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Nan LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Guozhan XiaDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Bin LiDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yang ZhangDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Hong HuDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yihua SunDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yawei ZhangDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiaqing XiangDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Dongchun MaDepartment of Thoracic Surgery, Anhui Chest Hospital, Hefei, China.
Yuan WengDepartment of Thoracic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
Shilei LiuDepartment of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou, China.
Chunyi JiaDepartment of Thoracic Surgery, Jilin Cancer Hospital, Changchun, China.
Bin QianDepartment of Thoracic Surgery, Jiang Du People's Hospital, Jiangdu, China.
Yajia GuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yuan LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shaoli SongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Haiquan ChenDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0001-7846-257X
Shanghai Medical College of Fudan University · CNAnhui Provincial Hospital · CNHenan Cancer Hospital · CNJiangnan University · CNJiangxi Provincial People's Hospital · CNJilin Province Tumor Hospital · CN

Funding

National Natural Science Foundation of China 81930073National Natural Science Foundation of China 82003285Pilot Project of Fudan University IDF159034Shanghai Anticancer Association EYAS project SACA-CY1A03Shanghai Municipal Key Clinical Specialty Project SHSLCZDZK02104Shanghai Municipal Science and Technology Major Project 2017SHZDZX01Shanghai Municipal Science and Technology Major Project VBH1323001/026
6 · The paper itself

Abstract

background

methodsThis was a prospective multicenter clinical trial (NCT03689439). Patients with cT1N0 subsolid nodules who were candidates for surgical resection were consecutively enrolled into the study. BS was performed preoperatively. The surgical plan could be changed if a positive result was detected. The primary endpoint was the incidence rate of the surgical plan being changed because of positive BS results. The secondary endpoint was the rate of positive BS findings and the rate of related complications.

resultsFrom November 2018 to July 2019, 691 patients were enrolled into the study. None of the patients had positive BS results and no surgical plans were changed by BS findings. There were 222 male and 469 female patients. The average age was 54.8 ± 3.7 years old. The average tumor diameter was 14.9 ± 4.2 mm. There were 282 patients with pure GGO nodules and 409 with part-solid nodules. A total of 470 patients had a single nodule, while 221 patients had multifocal lesions. The number of patients whose pathological diagnosis was invasive adenocarcinoma, minimally invasive adenocarcinoma, adenocarcinoma in situ and mucinous adenocarcinoma was 357, 293, 32 and nine, respectively. The number of patients who underwent lobectomy, segmentectomy and wedge resection was 234, 199 and 258, respectively.

conclusionsKEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: In this prospective study of 691 patients with cT1N0 subsolid lung cancer, no surgical plans were affected by positive bone scan findings. WHAT THIS STUDY ADDS: We suggest physicians consider canceling BS from preoperative workup for cT1 subsolid lung cancer patients. Clinical trial registry number: NCT03689439.

Indexed as

AdultAgedAged, 80 and overFemaleHumansLung NeoplasmsMaleMiddle AgedPreoperative PeriodProspective StudiesTechnetium Tc 99m MedronateTechnetium Tc 99m MedronateBone scintigraphycT1N0 subsolid lung cancerpreoperative workup

Identifiers

PMID33210466
PMCPMC7882389
OpenAlexW3104919575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.